Rare Community Profiles: How Dixie Commits to Supporting her Son and the MSMDS Community
source: shutterstock.com

Rare Community Profiles: How Dixie Commits to Supporting her Son and the MSMDS Community

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: How Dixie Commits to Supporting her Son and the MSMDS Community
ICYMI: Pancreatic and Thyroid Cancer Coverage Now Provided for Ontario Firefighters
felljagd3150 / Pixabay

ICYMI: Pancreatic and Thyroid Cancer Coverage Now Provided for Ontario Firefighters

  The International Association of Fire Fighters (IAFF) shared in March 2023 that firefighters in Ontario would now have presumptive pancreatic cancer and thyroid cancer coverage. Presumptive coverage means that…

Continue Reading ICYMI: Pancreatic and Thyroid Cancer Coverage Now Provided for Ontario Firefighters
FDA Grants Orphan Drug Designation to OM-301 for Multiple Myeloma
https://pixabay.com/en/thumbs-up-okay-good-well-done-2056022/

FDA Grants Orphan Drug Designation to OM-301 for Multiple Myeloma

  Have you ever heard of the Orphan Drug Act? This Act helped stimulate and advance the development of, and research into, therapeutics for individuals living with rare or underserved conditions. In…

Continue Reading FDA Grants Orphan Drug Designation to OM-301 for Multiple Myeloma
Ampreloxetine Failed the First Time but Emerged a Winner for Multiple System Atrophy
source: pixabay.com

Ampreloxetine Failed the First Time but Emerged a Winner for Multiple System Atrophy

  Theravance Biopharma’s late-stage failure suddenly became a jump-off point for treating multiple system atrophy (MSA) according to a recently published article in Neurology Live. After the failure of two…

Continue Reading Ampreloxetine Failed the First Time but Emerged a Winner for Multiple System Atrophy
How Preoperative Immunotherapy Can Change the MPM Treatment Landscape and Improve Outcomes
source: pixabay.com

How Preoperative Immunotherapy Can Change the MPM Treatment Landscape and Improve Outcomes

Historically, mesothelioma has been difficult to treat. Although treatment options exist, the cancer tends to respond poorly which results in a higher mortality rate. Improving patient care and outcomes (such…

Continue Reading How Preoperative Immunotherapy Can Change the MPM Treatment Landscape and Improve Outcomes
A Biomarker for Niemann-Pick Disease Type C Could Improve Congenital Disorders of Glycosylation Diagnosis
source: pixabay.com

A Biomarker for Niemann-Pick Disease Type C Could Improve Congenital Disorders of Glycosylation Diagnosis

Let’s start with a little vocabulary lesson. Today’s word? Biomarker. A biological marker, or biomarker, refers to some sort of measurable indicator of disease. For example, blood pressure, cellular gene…

Continue Reading A Biomarker for Niemann-Pick Disease Type C Could Improve Congenital Disorders of Glycosylation Diagnosis
NC Family Raises SYNGAP1 Awareness After Daughter’s Diagnosis
https://pixabay.com/en/dna-dns-biology-genetic-material-1388696/

NC Family Raises SYNGAP1 Awareness After Daughter’s Diagnosis

The first few years of Saylor Baysden’s life involved a good deal of medical confusion. Her family pursued testing, leading to two diagnoses in 2020-21: autism and epilepsy. But her…

Continue Reading NC Family Raises SYNGAP1 Awareness After Daughter’s Diagnosis
Rare Classroom: Anal Cancer
source: shutterstock

Rare Classroom: Anal Cancer

Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…

Continue Reading Rare Classroom: Anal Cancer